Abeona therapeutics cleared to initiate pivotal phase 3 clinical trial evaluating eb-101 gene therapy for recessive dystrophic epidermolysis bullosa

Abeona therapeutics cleared to initiate pivotal phase 3 clinical trial evaluating eb-101 gene therapy for recessive dystrophic epidermolysis bullosa.abeona therapeutics - fda removes clinical hold, co may proceed with viital study.abeona therapeutics inc - company expects to initiate viital study in q1 of 2020.
ABEO Ratings Summary
ABEO Quant Ranking